Background: Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all
the healthcare systems facing this very challenging issue. Aspirin continues to be the major …

Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone
or with P2Y 12-inhibitors are effective for prevention of atherothrombotic complications …

Arterial thrombosis is a leading cause of death and disability worldwide with no effective
bioassay for clinical prediction. As a symbolic feature of arterial thrombosis, severe stenosis …

Antiplatelet therapy resistance against acetylsalicylic acid (ASA) and/or clopidogrel in
coronary heart disease (CHD) is common with diabetes mellitus. One factor might involve …

Background: Hypertension is a risk factor of poor stroke outcomes and associated with
antiplatelet resistance. This study aimed to explore the efficacy and safety of ticagrelor …

Clopidogrel is an antiplatelet agent that is indicated for cardiovascular emergencies and
procedures. The drug, however, is subject to response variability leading to therapy …

Background: Platelet inhibitory therapy is prescribed to prevent arterial thromboembolism in
patients with atherosclerotic disease. Although taken by millions of people, around 30% are …

Platelet thrombosis is the main pathogeny resulting in the low curability of ischemic stroke, a
leading cause of mortality and disability worldwide. Metformin, a biguanide derivative that is …

Backgrounds Clopidogrel resistance (CR), which was manifested as the failure of platelet
inhibition in clopidogrel treatment, was likely to lead to cardiovascular events. Our study was …

Introduction Dual antiplatelet therapy with clopidogrel and aspirin is the current standard of
care in the management of patients with coronary artery disease (CAD) and acute coronary …